Joyce A O'Shaughnessy
Impact in
- Oncology top 0.1%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- PARP inhibition in cancer therapy
- Cancer Research top 0.2%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 105
- HER2/EGFR in Cancer Research 59
- Cancer Treatment and Pharmacology 54
- Colorectal Cancer Treatments and Studies 9
- Cancer Immunotherapy and Biomarkers 7
-
- Breast Cancer Treatment Studies 45
- Cancer Genomics and Diagnostics 8
- Co-authors
- William John Gradishar (5 shared papers)Paul Bhar (2 shared papers)Heather S. Shaw (1 shared paper)Michael Hawkins (1 shared paper)Sergei Tjulandin (1 shared paper)Neville G. P. Davidson (1 shared paper)Neil P. Desai (1 shared paper)Denise Aysel Yardley (8 shared papers)
- Journals
- Annals of Oncology (28 papers)Clinical Breast Cancer (19 papers)Journal of Clinical Oncology (18 papers)Clinical Cancer Research (12 papers)Breast Cancer Research and Treatment (10 papers)
- Partner nations
- United StatesUnited KingdomSpain
In The Last Decade
Joyce A O'Shaughnessy
167 papers receiving 18.9k citations
Joyce A O'Shaughnessy's Hit Papers
Peers
Comparison fields: 5 of 142
- Oncology 10.8k
- Cancer Research 4.5k
- Pulmonary and Respiratory Medicine 5.6k
- Genetics 808
- Biomaterials 829
Countries citing papers authored by Joyce A O'Shaughnessy
This map shows the geographic impact of Joyce A O'Shaughnessy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joyce A O'Shaughnessy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joyce A O'Shaughnessy more than expected).
Fields of papers citing papers by Joyce A O'Shaughnessy
This network shows the impact of papers produced by Joyce A O'Shaughnessy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joyce A O'Shaughnessy. The network helps show where Joyce A O'Shaughnessy may publish in the future.
Co-authors
The 25 scholars most cited alongside Joyce A O'Shaughnessy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 173 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab for Early Triple-Negative Breast Cancer Hit paper breakdown → | 2020 | 2258 |
| 2 | Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer Hit paper breakdown → | 2005 | 1796 |
| 3 | Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer Hit paper breakdown → | 2016 | 1544 |
| 4 | Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer Hit paper breakdown → | 2021 | 1197 |
| 5 | RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer Hit paper breakdown → | 2011 | 858 |
| 6 | Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer Hit paper breakdown → | 2019 | 697 |
| 7 | Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer Hit paper breakdown → | 2018 | 680 |
| 8 | Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer Hit paper breakdown → | 2011 | 678 |
| 9 | Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study Hit paper breakdown → | 2018 | 668 |
| 10 | Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer Hit paper breakdown → | 2021 | 581 |
| 11 | MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer Hit paper breakdown → | 2017 | 558 |
| 12 | 2005 | 554 | |
| 13 | 2009 | 467 | |
| 14 | 2008 | 352 | |
| 15 | 2017 | 340 | |
| 16 | Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. | 2002 | 318 |
| 17 | Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial Hit paper breakdown → | 2021 | 317 |
| 18 | Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer Hit paper breakdown → | 2024 | 263 |
| 19 | Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer Hit paper breakdown → | 2024 | 261 |
| 20 | 2014 | 255 |
About Joyce A O'Shaughnessy
Joyce A O'Shaughnessy is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 173 papers that have together received 19.5k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (59 papers), Cancer Treatment and Pharmacology (54 papers), Breast Cancer Treatment Studies (45 papers), Advanced Breast Cancer Therapies (43 papers), Estrogen and related hormone effects (11 papers), Colorectal Cancer Treatments and Studies (9 papers), Cancer Genomics and Diagnostics (8 papers) and Cancer Immunotherapy and Biomarkers (7 papers). The work is most often cited by research in Oncology (10.8k citations), Cancer Research (4.5k citations), Pulmonary and Respiratory Medicine (5.6k citations), Genetics (808 citations) and Biomaterials (829 citations). Joyce A O'Shaughnessy has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include William John Gradishar, Paul Bhar, Heather S. Shaw, Michael Hawkins, Sergei Tjulandin, Neville G. P. Davidson, Neil P. Desai, Denise Aysel Yardley, John Pippen and Veronique C Dieras. Their work appears in journals such as Annals of Oncology, Clinical Breast Cancer, Journal of Clinical Oncology, Clinical Cancer Research and Breast Cancer Research and Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.